Immunotherapeutic perspective for bispecific antibodies

Immunology Today

Volumn 21, Issue 8, 2000, Pages 391-397

  Van Spriel, Annemiek B ^a   Van Ojik, Heidi H ^a   Van de Winkel, Jan G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD11B ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL PEPTIDASE IV; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; BIOENGINEERING; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; ERYTHROCYTE; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MACROPHAGE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BISPECIFIC; CANDIDA ALBICANS; CLINICAL TRIALS; HUMANS; LYMPHOCYTES; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; NEUTROPHILS; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 0033859727     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(00)01659-5     Document Type: Review

References (55)

1. An overview of monoclonal antibody therapy of cancer
2. Immunotherapeutic potential of bispecific antibodies
3. 2 antibody containing thioether-linked Fab'γ fragments
4. Mix and match: Building manifold binding sites
5. An efficient route to human bispecific IgG
6. Design and production of novel tetravalent bispecific antibodies
7. A dimeric bispecific miniantibody combines two specificities with avidity
8. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulinγ1 Fc or CH3 region
9. Immunotoxins: An update
10. Cytolytic and cytostatic properties of an anti-human FcγRI (CD64) x epidermal growth factor bispecific fusion protein
11. Resolution of cutaneous inflammation after local elimination of macrophages
12. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
13. Dendritic cells and the control of immunity
14. Recombinant lipid-tagged antibody fragments as functional cell-surface receptors
15. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
16. Roles of multiple accessory molecules in T-cell activation
17. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
18. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model
19. Bispecific antibodies in cancer therapy
20. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tum
21. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
22. Fc receptors are required in passive and active immunity to melanoma
23. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
24. Generation of Her2/neu-specific cytotoxic neutrophils in vivo: Efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcγ Receptor I bispecific antibodies
25. The FcγRI (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR γ-chain
26. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice
27. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy
28. FcαRI-directed bispecific antibody improves effector cell recruitment for CD20-directed immunotherapy
29. Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils
30. + liver Kupffer cells: Reappraisal of the role of immunoglobulin A in immunity
31. Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro
32. Targeting HIV-1 to FcγR on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells
33. Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice
34. Transfer of immune complexes from erythrocyte CR1 to mouse macrophages
35. Bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement
36. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte colony-stimulating factor (filgrastim) for treatment of advanced breast cancer
37. Clinical experience with CD64-directed immunotherapy
38. Immunotherapy with bispecific antibody MDX-H210 (anti-HER-2 x anti-CD64) combined with GM-CSF in HER-2-positive hormone resistant prostate cancer
39. Bispecific antibodies in cancer therapy, from the laboratory to the clinic
40. A phase I study of a HER2/neu bispecific antibody with granulocyte colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
41. Preliminary trial of specific targeting therapy against malignant glioma
42. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2
43. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
44. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies
45. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies
46. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
47. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII
48. A phase I trial of the epidermal growth factor receptor-directed bispecific antibody MDX-447 in patients with solid tumors
49. Adoptive immunotherapy in ovarian cancer with monocyte derived activated killer cells mixed with anti HER-2/neu x anti FcγRI bispecific antibody
50. An activating immunoreceptor complex formed by NKG2D and DAP10
51. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components
52. Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and x loci and expression of fully human antibodies